Breaks Categories: News

TuesdaySep 24, 2024 10:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/3khUt About Nutriband Inc.…

Continue Reading

MondaySep 23, 2024 11:20 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/P0zd8 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

Continue Reading

FridaySep 20, 2024 12:45 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

Continue Reading

ThursdaySep 19, 2024 11:25 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has been awarded a patent by the United States Patent and Trademark Office; the patent is titled “Formulations Comprising Triptan Compounds.” According to the announcement, the patent was issued on Sept. 17, 2024, and is slated to expire in 2030. The company noted that the patent claims a pharmaceutical composition, a method of treating migraine via intranasal administration and an intranasal delivery system for Tosymra(R). “We believe this patent further solidifies Tosymrain the market as a differentiated drug with a differentiated administration…

Continue Reading

ThursdaySep 19, 2024 11:10 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Expansion of Its Telehealth Services Nationwide, New Service

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a partnership with Lyric Health, a comprehensive virtual care provider. This partnership, which entails integrating HealthLynked with Lyric Health, enables the company to expand its telehealth services nationwide to all 50 states. As part of this expansion, the company has introduced its new Virtual Urgent Care service, which enables members to connect with a licensed physician within an average of 20 minutes. Additionally, HealthLynked intends to launch its Virtual Primary Care service, which will allow users to set future appointments with primary care physicians, establishing ongoing relationships with virtual doctors.…

Continue Reading

WednesdaySep 18, 2024 10:13 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox

Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is a biopharmaceutical company with marketed products and a pipeline of development candidates. Tonix’s TNX-801, a live-virus vaccine candidate, could potentially offer a more viable solution to address the growing global mpox crisis. TNX-801 shows promise because it appears to align with the preferred target product profile (“TPP”) recently issued by the World Health Organization (“WHO”). The TPP emphasizes a well-tolerated, single-dose vaccine that can be administered, shipped and stored in Africa and around the world. Jynneos(R) and ACAM2000(R), two FDA-approved vaccines for mpox, do not fully meet WHO’s TPP. Thus, TNX-801 potentially offers a…

Continue Reading

TuesdaySep 17, 2024 8:55 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress on the development of AVERSA Fentanyl, with a target date of submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2025. To view the full press release, visit https://ibn.fm/AfJJt About Nutriband Inc. Nutriband is primarily…

Continue Reading

MondaySep 16, 2024 10:56 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, will be meeting in-person with the U.S. Food and Drug Administration (“FDA”) before the end of November 2024. The company announced that the meeting, which will focus on discussions about the development of the company’s proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (“ALS”), will include key FDA representatives, including the organization’s director of the Office on New Drugs and director of the Office of Neuroscience, as well as the Division of Neurology 1 (“DN1”) review team and key…

Continue Reading

MondaySep 16, 2024 10:34 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports TNX-801 Aligns with WHO Preferred TPP for Mpox Vaccines

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, is reporting that the World Health Organization’s (“WHO”) preferred target product profile (“TPP”) aligns with the characteristics of its proprietary TNX-801 (horsepox, live virus) vaccine; Tonix is developing the vaccine for mpox (formerly known as monkeypox). WHO released the TPP at the Mpox Research and Innovation Scientific Conference, which was held Aug. 29–30, 2024, According to the announcement, key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment and stability at ambient temperature. “The characteristics of TNX-801…

Continue Reading

MondaySep 16, 2024 9:35 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced plans to host a scientific webinar to discuss the plaque psoriasis landscape, current treatment methods, and existing unmet needs in treating mild to moderate plaque psoriasis. The virtual panel discussion will also explore intralesional injections of the company’s novel anti-IL-17A/F VHH single domain VHH antibodies as a promising solution. Other topics will include an introduction to single domain VHH antibodies and the company’s pipeline, with panelists also reviewing the biological drug development…

Continue Reading